Catalent (CTLT:NYSE) Investor Relations Material

Overview

Catalent, Inc., a global leader in drug development and manufacturing solutions, has announced its plans to revolutionize the industry by catering to a wide range of products, including prescription drugs, over-the-counter medications, dietary supplements, cosmetics, and animal health medicinal preparations. With subsidiaries specializing in Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services, the company aims to provide formulation, development, and manufacturing services across various technologies. Additionally, Catalent's FlexDirect and FastChain services offer direct-to-patient and demand-led clinical supply solutions, respectively. Headquartered in Somerset, New Jersey, the company serves pharmaceutical, biotechnology, consumer health, medical devices, and cosmetics industries.

Frequently Asked Questions

What is Catalent's ticker?

Catalent's ticker is CTLT

What exchange is Catalent traded on?

The company's shares trade on the NYSE stock exchange

Where are Catalent's headquarters?

They are based in Somerset, New Jersey

How many employees does Catalent have?

There are 5001-10,000 employees working at Catalent

What is Catalent's website?

It is catalent.com

What type of sector is Catalent?

Catalent is in the Healthcare sector

What type of industry is Catalent?

Catalent is in the Drugs - Generic industry

Who are Catalent's peers and competitors?

The following five companies are Catalent's industry peers:

- Fibrocell Science Inc

- Mallinckrodt

- Karyopharm Therapeutics

- Akorn Inc.

- Collegium Pharmaceutical